Life Scientist > Lab Technology

XRT secures new investors

29 August, 2005 by Helen Schuller

Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has secured new investment funds from a syndicate of UK investors including an undisclosed institutional group.


Norwood Abbey and AWI continue chemical mulesing program

26 August, 2005 by Ruth Beran

Norwood Abbey (ASX:NAL) and Australian Wool Innovation (AWI) have signed an agreement to enter into phase II development of a non-surgical mulesing technology to prevent sheep flystrike using Norwood's needle-free injection technology.


BioDiem reports new chair, increased loss

26 August, 2005 by Ruth Beran

Australian corporate leader Hugh Morgan is the new chairman of Melbourne-based flu vaccine company BioDiem (ASX:BDM) which has reported an increased loss of AUD$4.2 million in 2004-05, up 32 per cent from the last financial year.


Why investors are the missing link to biotech's success

26 August, 2005 by Peter Andrews

Scientists, industry and government are doing their bit to develop the Australian biotechnology industry, writes Peter Andrews -- so where are the investors?


CSL grants Merck licence for Iscomatrix

24 August, 2005 by Ruth Beran

Australia's biggest biotech, Melbourne's CSL (ASX:CSL) has signed a license and option agreement with Merck & Co, granting the New Jersey-based pharmaceutical company certain rights and options to use CSL's Iscomatrix adjuvant in its pipeline of investigational vaccine products.


Sales drive up CogState revenues

24 August, 2005 by Helen Schuller

Melbourne-based neurodiagnostic specialist CogState (ASX:CGS) has reported revenues of AUD$1.5 million for the financial year ending June 30 2005, nearly three times more than the previous corresponding period, largely through sales to major pharmaceutical companies and research institutions.


Event to focus on funding

23 August, 2005 by Staff Writers

A breakfast meeting in Sydney this Friday will explore ways in which technology-based companies can get their hands on Commonwealth and NSW government grants.


$1m up for grabs in Qld grants

22 August, 2005 by Staff Writers

The Queensland government is offering $950,000 to local entrepreneurs in its start-up scheme, double the amount offered in previous years.


Find the right investor, biotechs warned

18 August, 2005 by Helen Schuller

Biotechnology companies should not take money from just anybody, a meeting in Sydney heard this morning.


In brief: Select Vaccines, Life Therapeutics, Chemeq

17 August, 2005 by Ruth Beran

Select Vaccines' (ASX:SLT) executive chairman Jeremy Cooper has retired as a director and will be replaced by Robin Beaumont as non-executive chairman. Dr Martin Soust has become the Select Vaccines' full-time managing director, relinquishing his role as part-time CEO at Premier Bionics (ASX:PBI) but remaining with the company as a non-executive director. Peter Marks has been appointed as a non-executive director for Select Vaccines.


Giaconda aims for Sept IPO

17 August, 2005 by Helen Schuller

Sydney-based gastrointestinal drug development company Giaconda, has opened its initial public offering and plans to list on the ASX in late September, with the aim of raising AUD$6 million.


IDT posts record revenue, profit and dividends

17 August, 2005 by Ruth Beran

Pharmaceutical manufacturing and drug development company Institute of Drug Technology Australia (ASX:IDT) has reported an operating profit after tax of AUD$4.5 million for the year ended June 30, representing an increase of 5 per cent over the previous year.


Resonance to provide FerriScan to US research institutes

17 August, 2005 by Helen Schuller

Resonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT) and formerly known as Inner Vision Biometrics, has agreed to provide its FerriScan diagnostic test to the New England Research Institutes (NERI) for use in its clinical studies.


Boost for medical research in Queensland

17 August, 2005 by Helen Schuller

Medical research in Queensland has won a jackpot, with unclaimed first division lotto prizes to be transformed into grants for research and equipment.


Why biotech companies don't work

17 August, 2005 by Iain Scott

Australian Biotechnology News editor-in-chief Iain Scott spoke with renowned industry analyst Cynthia Robbins-Roth about what it will take to keep biotech alive.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd